These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19606942)

  • 1. The pharmacology of esomeprazole and its role in gastric acid related diseases.
    Saccar CL
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1113-24. PubMed ID: 19606942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole: a clinical review.
    Johnson TJ; Hedge DD
    Am J Health Syst Pharm; 2002 Jul; 59(14):1333-9. PubMed ID: 12132559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
    Tonini M; Vigneri S; Savarino V; Scarpignato C
    Dig Liver Dis; 2001 Oct; 33(7):600-6. PubMed ID: 11816552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esomeprazole: update and clinical review.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(4):189-99. PubMed ID: 12481170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esomeprazole: potent acid suppression in the treatment of acid-related disorders.
    Morgner-Miehlke A; Petersen K; Miehlke S; Labenz J
    Expert Rev Clin Immunol; 2005 Nov; 1(4):511-27. PubMed ID: 20477595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omeprazole: a new approach to gastric acid suppression.
    Buhl K; Clearfield HR
    Am Fam Physician; 1990 Apr; 41(4):1225-7. PubMed ID: 2321497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.
    Klotz U
    Arzneimittelforschung; 2009; 59(6):271-82. PubMed ID: 19634508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esomeprazole for acid peptic disorders.
    Kale-Pradhan PB; Landry HK; Sypula WT
    Ann Pharmacother; 2002 Apr; 36(4):655-63. PubMed ID: 11918517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharma clinics medication of the month. Esomeprazole].
    Louis E
    Rev Med Liege; 2002 Sep; 57(9):610-2. PubMed ID: 12440351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
    Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-isomer drugs: true therapeutic advances.
    Andersson T
    Clin Pharmacokinet; 2004; 43(5):279-85. PubMed ID: 15080761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
    Lindberg P; Keeling D; Fryklund J; Andersson T; Lundborg P; Carlsson E
    Aliment Pharmacol Ther; 2003 Feb; 17(4):481-8. PubMed ID: 12622756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.